11
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Condition(s):Acute Myeloid Leukemia NOSLast Updated:April 20, 2017Withdrawn
Leukine: 749 Clinical Trials, Page 2 of 75
Hide Studies Not Open or Pending
12
Sargramostim (GM-CSF) + PD-1
Condition(s):Unresectable Melanoma; Metastatic Melanoma; Stage III Melanoma; Stage IV MelanomaLast Updated:October 13, 2022Recruiting
13
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease
Condition(s):Dementia Alzheimer’s TypeLast Updated:April 7, 2017Withdrawn
14
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
Condition(s):Drug Kinetics; Drug Effects on PhysiologyLast Updated:October 3, 2022Completed
15
Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Condition(s):Down SyndromeLast Updated:November 14, 2022Not yet recruiting
16
Leukine (Sargramostim) for Parkinson’s Disease
Condition(s):Parkinson’s DiseaseLast Updated:May 24, 2016Completed
17
A Phase II/III Study of Sargramostim
Condition(s):COVID-19Last Updated:November 3, 2021Completed
18
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Condition(s):Hereditary Pulmonary Alveolar ProteinosisLast Updated:September 1, 2020Completed
19
A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva
Condition(s):PeriodontitisLast Updated:October 29, 2008Completed
20
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin’s Lymphoma
Condition(s):Lymphoma, FollicularLast Updated:December 27, 2013Terminated